ALXO earnings analysis
What we found in ALXO's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
ALX Oncology's Q1 2026 10-Q reported a net loss of $17.9 million, or $0.17 per share, significantly better than the consensus estimate of -$0.16. This improvement was aided by a 43% reduction in R&D expenses to $13.6 million, allowing cash and investments to increase to $169.1 million, despite ongoing operational losses.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Significant EPS Beat
- Q1 2026 EPS reported at -$0.17, beating estimates of -$0.16.
- Reduced R&D Spending
- R&D expenses dropped by $10.3 million (43%) to $13.6 million compared to Q1 2025.
- Increased Cash Position
- Cash, cash equivalents, and investments grew to $169.1 million.
- Narrower Operating Loss
- Operating loss improved by $12.9 million (40%) to $18.966 million from $31.820 million in Q1 2025.
- Lower General & Admin Expenses
- General and administrative expenses decreased by $2.57 million (32%) to $5.36 million for Q1 2026.
- Successful Clinical Trials
- Advancement of evorpacept with promising data presented from ongoing clinical trials.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Ongoing Net Losses
- Net losses for Q1 2026 were $17.9 million, indicating continued financial challenges.
- Regulatory Risks
- Both evorpacept and ALX2004 are subject to unpredictable FDA approval processes.
- Dependence on Key Personnel
- As a clinical-stage company, loss of key personnel could critically affect operations.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-0.17
What they said about what is next.
No explicit numeric guidance provided; forward outlook deferred to future announcements.
The filing reads better than the one before it.
What came before.
- 10-K · March 9, 2026
- ALX Oncology is a clinical‑stage biotech focused on developing evorpacept (CD47 blocker) and an EGFR‑targeted ADC (ALX2004). The 10‑K highlights meaningful Phase 2 efficacy (ASPEN‑06) and biomarker signal while the…
- 10-Q · August 12, 2025
- ALX reported a narrower Q2 2025 net loss of $25.9M (EPS $(0.49)) versus Q2 2024 net loss of $39.4M (EPS $(0.76)), driven primarily by a reduction in R&D spending. Operating cash use improved to $(48.1)M for the six…
- 10-Q · May 8, 2025
- ALX reported a narrower net loss of $30,754,000 in Q1 2025 versus $35,581,000 in Q1 2024 (EPS improved to $(0.58) from $(0.71)). Research and development expense declined meaningfully to $23,888,000 from $31,717,000 as…
- 10-K · March 6, 2025
- ALX Oncology is a clinical-stage immuno-oncology company advancing evorpacept, a next‑generation CD47 blocker designed with an inactivated Fc to improve tolerability and combination potential. Recent clinical readouts…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing ALXO makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever